SEC Form 4 · accession 0001415889-17-000282
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrence O Moore
Officer — EVP, CHIEF COMMERCIAL OFFICER
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 7:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 14, 2017 | M | 87,128 | $19.61 | A | 90,759 | D | |
| Common StockF3 | Feb 14, 2017 | S | 89,088 | $39.6863 | D | 1,671 | D | |
| Common Stock | Feb 15, 2017 | M | 1,700 | $19.61 | A | 3,371 | D | |
| Common Stock | Feb 15, 2017 | S | 1,700 | $39.65 | D | 1,671 | D | |
| Common Stock | Feb 16, 2017 | M | 17,421 | $19.61 | A | 19,092 | D | |
| Common Stock | Feb 16, 2017 | M | 19,687 | $27.20 | A | 38,779 | D | |
| Common Stock | Feb 16, 2017 | M | 29,644 | $34.45 | A | 68,423 | D | |
| Common StockF4 | Feb 16, 2017 | S | 66,752 | $39.8807 | D | 1,671 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $19.61 | Feb 14, 2017 | M | 12,747 | D | — | Aug 18, 2023 | Common Stock | 12,747 | 7,649 | D |
| Stock Option (right to buy)F5 | $19.61 | Feb 14, 2017 | M | 74,381 | D | — | Aug 18, 2023 | Common Stock | 74,381 | 55,223 | D |
| Stock Option (right to buy)F5 | $19.61 | Feb 15, 2017 | M | 1,700 | D | — | Aug 18, 2023 | Common Stock | 1,700 | 53,523 | D |
| Stock Option (right to buy)F5 | $19.61 | Feb 16, 2017 | M | 17,421 | D | — | Aug 18, 2023 | Common Stock | 17,421 | 36,102 | D |
| Stock Option (right to buy)F6 | $27.20 | Feb 16, 2017 | M | 19,687 | D | — | Mar 6, 2024 | Common Stock | 19,687 | 13,125 | D |
| Stock Option (right to buy)F7 | $34.35 | Feb 16, 2017 | M | 29,644 | D | — | Mar 19, 2025 | Common Stock | 29,644 | 90,356 | D |
Explanation of responses
- F1Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.
- F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F525% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- F625% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- F725% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.